Equity Profile

IMNM

Immunome, Inc.

Health CareBiotechnology$3.0B

Nov4Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Immunome, Inc. is a biotechnology company focused on developing therapies that harness the power of the immune system to fight diseases, including cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Understanding revenue trends is crucial for assessing the company's market performance and the success of its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IMNM Q2-2026 Earnings Preview

Context

Company Snapshot

Immunome, Inc. is a biotechnology company focused on developing therapies that harness the power of the immune system to fight diseases, including cancer. As part of the health care sector, its innovations could significantly impact treatment options and patient outcomes in the rapidly evolving biotech landscape.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-68.16%

Avg Stock Reaction

-1.95%

Last Quarter Recap

In the last quarter, Immunome reported an EPS of -$0.48, which was better than the expected -$0.60, leading to a slight positive reaction in the stock price. However, the company did not provide revenue figures or specific guidance, leaving some uncertainty.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, market expectations are mixed as there are no analyst estimates available, and the company has a history of both beating and missing EPS expectations. Investors will be closely watching for any signs of improvement in profitability and revenue.

Bull Case

If Immunome can demonstrate significant progress in its clinical trials and report better-than-expected EPS, it could signal strong future growth, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to show improvement in its financials or clinical trial outcomes, it could lead to further declines in stock price, especially given its recent history of disappointing earnings.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of ongoing clinical trials?

Investors will be keen to understand the timeline and potential outcomes of these trials, as they are critical for future revenue generation.

Will there be any guidance on expected revenue for the upcoming quarters?

Clear revenue guidance is essential for setting expectations and could significantly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Immunome's clinical trials to yield significant breakthroughs, which could lead to better-than-expected financial results.

Supporting Evidence

The options market indicates a high level of uncertainty, suggesting that traders expect a substantial move, which could be positive if trial results are favorable.

Immunome's recent EPS surprises, while mixed, show that the company has the potential to outperform expectations.

The lack of analyst estimates may mean that the market is not fully accounting for the potential upside from successful trial outcomes.

Key Risk

If clinical trial results are announced that exceed expectations, it could dramatically shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on whether Immunome can turn around its recent performance and provide a clearer path to profitability.

Bull Confirmed If

A reported EPS improvement to -$0.30 or better alongside positive updates on clinical trials would confirm the bull case.

Bear Confirmed If

An EPS of -$0.60 or worse, coupled with negative news on clinical trials, would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±44.3%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating high uncertainty around the earnings report.

Options are pricing ±44.3% while IMNM has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

54.2%

Calls (11K)P/C Ratio: 5.31Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunome beats expectations and raises guidance, history suggests a potential stock increase of around +0.50% on the first day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement, reflecting cautious sentiment.

Miss

Should the company miss expectations, history suggests a potential decline of around -3.42% on the first day, which could further shake investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timelines for clinical trial results.
2Management's commentary on expected revenue growth for the next quarter.
3Insights into any new partnerships or collaborations that could enhance product development.
4Details on cost management strategies and their impact on future profitability.
5Responses to analyst questions regarding competitive positioning in the biotech space.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Cirrus Logic, Inc.

Company Snapshot

Immunome, Inc. is a biotechnology company focused on developing therapies that harness the power of the immune system to fight diseases, including cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Understanding revenue trends is crucial for assessing the company's market performance and the success of its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IMNM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-68.16%

Avg Stock Reaction

-1.95%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Immunome can demonstrate significant progress in its clinical trials and report better-than-expected EPS, it could signal strong future growth, leading to a positive market reaction.

Bear Case

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of ongoing clinical trials?

Investors will be keen to understand the timeline and potential outcomes of these trials, as they are critical for future revenue generation.

Will there be any guidance on expected revenue for the upcoming quarters?

Clear revenue guidance is essential for setting expectations and could significantly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Immunome's clinical trials to yield significant breakthroughs, which could lead to better-than-expected financial results.

Supporting Evidence

The options market indicates a high level of uncertainty, suggesting that traders expect a substantial move, which could be positive if trial results are favorable.

Immunome's recent EPS surprises, while mixed, show that the company has the potential to outperform expectations.

The lack of analyst estimates may mean that the market is not fully accounting for the potential upside from successful trial outcomes.

Key Risk

If clinical trial results are announced that exceed expectations, it could dramatically shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on whether Immunome can turn around its recent performance and provide a clearer path to profitability.

Bull Confirmed If

A reported EPS improvement to -$0.30 or better alongside positive updates on clinical trials would confirm the bull case.

Bear Confirmed If

An EPS of -$0.60 or worse, coupled with negative news on clinical trials, would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±44.3%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating high uncertainty around the earnings report.

Options are pricing ±44.3% while IMNM has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

54.2%

Calls (11K)P/C Ratio: 5.31Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunome beats expectations and raises guidance, history suggests a potential stock increase of around +0.50% on the first day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement, reflecting cautious sentiment.

Miss

Should the company miss expectations, history suggests a potential decline of around -3.42% on the first day, which could further shake investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timelines for clinical trial results.
2Management's commentary on expected revenue growth for the next quarter.
3Insights into any new partnerships or collaborations that could enhance product development.
4Details on cost management strategies and their impact on future profitability.
5Responses to analyst questions regarding competitive positioning in the biotech space.